Literature DB >> 3669094

Transfer dysphagia in a patient with the rare combination of scleroderma and ankylosing spondylitis.

P Witt, E Thomas.   

Abstract

Esophageal involvement in scleroderma is generally confined to the body, manifested manometrically as impaired motility and decreased lower esophageal sphincter tone. Pharyngeal dysfunction has not been recognized. This is a report of a patient with the rare combination of scleroderma and ankylosing spondylitis, whose presenting complaint was transfer dysphagia due to impaired relaxation of the upper esophageal spincter as a result of tight overlying cervical skin, or sclerodermatous involvement of the sphincter itself.

Entities:  

Mesh:

Year:  1987        PMID: 3669094      PMCID: PMC2625594     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  5 in total

1.  Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications.

Authors:  M B Orringer; L Dabich; C J Zarafonetis; H Sloan
Journal:  Ann Thorac Surg       Date:  1976-08       Impact factor: 4.330

2.  Disorders of the lower esophageal sphincter.

Authors:  R S Fisher; S Cohen
Journal:  Annu Rev Med       Date:  1975       Impact factor: 13.739

3.  Ankylosing spondylitis, lymphoma and scleroderma--a unique conjunction.

Authors:  J A O'Hare; D Murnaghan
Journal:  Ir J Med Sci       Date:  1982-11       Impact factor: 1.568

4.  The microvascular pathogenesis of scleroderma: an hypothesis.

Authors:  J F Fries
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

5.  Letter: HL-A antigens in progressive systemic sclerosis (scleroderma).

Authors:  B S Rabin; G P Rodnan; S Bassion; T J Gill
Journal:  Arthritis Rheum       Date:  1975 Jul-Aug
  5 in total
  3 in total

1.  Unusual association of systemic sclerosis and ankylosing spondylitis.

Authors:  Cinira S Soledade; Percival D Sampaio-Barros; Adil M Samara; João Francisco Marques-Neto
Journal:  Clin Rheumatol       Date:  2004-08-27       Impact factor: 2.980

Review 2.  Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.

Authors:  Avgoustina Kyriakou; Konstantinos Parperis; Elena Nikiphorou; Savvas Psarelis
Journal:  Rheumatol Int       Date:  2021-01-12       Impact factor: 2.631

3.  Sacroiliitis Detected by Magnetic Resonance Imaging in Patients With Systemic Sclerosis.

Authors:  Didem Arslan; İpek Türk; Erkan Kozanoğlu; Özlem Kudaş; Bayram Kelle; Hakan Sakalli
Journal:  Arch Rheumatol       Date:  2020-01-03       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.